KCPG
ALNY icon

Kavar Capital Partners Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Kavar Capital Partners Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6
Closed – – 140
2014
Q1 		$0 Sell
6
-2
-25% -$155 ﹤0.01% 529
2013
Q4 		$0 Buy
+8
New +$477 ﹤0.01% 499

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Kavar Capital Partners Group's ALNY Position: Q2 2014 in Review

Kavar Capital Partners Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2014, closing a stake of 6 shares.

Kavar Capital Partners Group first reported a position in ALNY in Q4 2013 and held it in 2 quarters. The position peaked at $0 in Q1 2014. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • Kavar Capital Partners Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Kavar Capital Partners Group sold 6 Alnylam Pharmaceuticals shares in Q2 2014.
  • Kavar Capital Partners Group first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Kavar Capital Partners Group's Alnylam Pharmaceuticals position peaked at $0 in Q1 2014.
  • 194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Kavar Capital Partners Group's 13F filing for Q2 2014, filed 25 Jan 2019.